111 (NASDAQ:YI) Given Sell (E+) Rating at Weiss Ratings

111 (NASDAQ:YI)‘s stock had its “sell (e+)” rating reaffirmed by investment analysts at Weiss Ratings in a note issued to investors on Tuesday,Weiss Ratings reports.

111 Price Performance

Shares of NASDAQ:YI opened at $6.99 on Tuesday. 111 has a 1 year low of $4.14 and a 1 year high of $12.60. The company has a market capitalization of $60.39 million, a PE ratio of -10.92 and a beta of 0.44. The business has a fifty day moving average price of $7.72 and a two-hundred day moving average price of $7.62.

111 (NASDAQ:YI) last released its earnings results on Thursday, June 19th. The company reported ($0.20) earnings per share for the quarter. The business had revenue of $486.35 million for the quarter.

Institutional Investors Weigh In On 111

Institutional investors and hedge funds have recently modified their holdings of the company. JPMorgan Chase & Co. boosted its stake in 111 by 43,619.9% during the fourth quarter. JPMorgan Chase & Co. now owns 306,039 shares of the company’s stock valued at $191,000 after buying an additional 305,339 shares during the period. FIL Ltd bought a new position in 111 in the 4th quarter worth about $450,000. Deuterium Capital Management LLC purchased a new stake in shares of 111 in the 1st quarter valued at about $81,000. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of 111 during the 1st quarter valued at about $92,000. 21.32% of the stock is owned by hedge funds and other institutional investors.

111 Company Profile

111, Inc engages in the provision of pharmaceutical products and medical services through online retail pharmacy and indirectly through offline pharmacy network. It operates through the B2C and B2B segments. The B2C segment engages in the sale of pharmaceutical and other health and wellness products directly to consumers through 1 Drugstore and its offline pharmacies.